Takeda Pharmaceutical Co. Ltd. Takes $1.37 Million Position in Equillium, Inc. (NASDAQ:EQ)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of Equillium, Inc. (NASDAQ:EQ) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium comprises approximately 5.2% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 4th biggest holding. Takeda Pharmaceutical Co. Ltd. owned about 5.15% of Equillium as of its most recent SEC filing.

Separately, DCF Advisers LLC lifted its stake in shares of Equillium by 91.0% in the 4th quarter. DCF Advisers LLC now owns 62,947 shares of the company’s stock valued at $47,000 after purchasing an additional 29,985 shares during the period. 27.05% of the stock is owned by hedge funds and other institutional investors.

Equillium Stock Performance

Shares of NASDAQ EQ opened at $0.76 on Thursday. The company has a market capitalization of $26.86 million, a PE ratio of -5.41 and a beta of 1.87. The company’s fifty day moving average price is $0.77 and its 200 day moving average price is $0.80. Equillium, Inc. has a 1 year low of $0.49 and a 1 year high of $2.45.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.